HuGE Literature Finder
Records
1
-
6
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine. Cancer chemotherapy and pharmacology 2021 Feb . Liu Duo, Li Xuehua, Li Xiang, Wang Huiqi, Dong M |
Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men. Cancers 2020 May 12 (5): . Ke Chien-Chih, Chen Lih-Chyang, Yu Chia-Cheng, Cheng Wei-Chung, Huang Chao-Yuan, Lin Victor C, Lu Te-Ling, Huang Shu-Pin, Bao Bo-Yi |
Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research 2017 Mar 120 133-137. Pellicer Marta, García-González Xandra, García María I, Robles Luis, Grávalos Cristina, García-Alfonso Pilar, Pachón Vanessa, Longo Federico, Martínez Virginia, Blanco Carolina, Iglesias Irene, Sanjurjo María, López-Fernández Luis |
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. British journal of cancer 2015 Mar 112 (5): 857-65. Teft W A, Welch S, Lenehan J, Parfitt J, Choi Y-H, Winquist E, Kim R |
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. British journal of clinical pharmacology 2010 Aug 70 (2): 222-33. Sai Kimie, Saito Yoshiro, Tatewaki Naoko, Hosokawa Masakiyo, Kaniwa Nahoko, Nishimaki-Mogami Tomoko, Naito Mikihiko, Sawada Jun-Ichi, Shirao Kuniaki, Hamaguchi Tetsuya, Yamamoto Noboru, Kunitoh Hideo, Tamura Tomohide, Yamada Yasuhide, Ohe Yuichiro, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Matsumura Yasuhiro, Saijo Nagahiro, Okuda Haruhi |
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Aug 9 (9): 3246-53. Mathijssen Ron H J, Marsh Sharon, Karlsson Mats O, Xie Rujia, Baker Sharyn D, Verweij Jaap, Sparreboom Alex, McLeod Howard |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 10, 2022
- Content source: